Liaoning Beifeng Pharmaceutical

Liaoning Beifeng Pharmaceutical Co., Ltd. (formerly known as Liaoning Kangyuan Huawei Pharmaceutical Co., Ltd.) is a Chinese pharmaceutical company specializing in the research, development, production, and sales of active pharmaceutical ingredients (APIs) and chemical intermediates. Founded in 2008 and based in Benxi, Liaoning Province, the company operates as a subsidiary of Jiangsu Kanion Pharmaceutical Co., Ltd. Liaoning Beifeng Pharmaceutical's product portfolio includes key APIs such as Perampanel (for epilepsy), Linagliptin (for type 2 diabetes), and Ipratropium Bromide (for respiratory conditions). The company is recognized as the first domestic manufacturer in China to obtain generic approval for Perampanel API. It operates GMP-compliant manufacturing facilities and serves both domestic and international markets.